罗氏Roche Holdings（RHHBY）2013年年度报告「OTC」.pdf

1、Annual ReportKey figuresTotal Shareholder Return 2013The value of CHF 100 4 invested 1/1/2013,for the period ending 31/12/2013 Roche GS,Price=249.20 Roche B,Price=247.40 Peer Set Index110130120140150160100Dec2012FebAprJunAugOctDec2013140137134Group sales46,780million CHF+6%(CER)1Core operating profi

2、t17,904million CHF+8%(CER)Core earnings per share14.27CHF+10%(CER)Operating free cash flow16,381million CHF+5%(CER)IFRS 2 net income11,373million CHF+22%(CER)Dividend 37.80CHF+6%A sustainable company339,350Patients in clinical trials21,000,000Patients treated 585,080Employees 6A global leader in inn

3、ovationNo.1 in biotechNo.1 in oncologyNo.1 in in vitro diagnosticsNo.1 in hospital markets1 CER:Constant exchange rates(average full-year 2012).2 IFRS:International Financial Reporting Standards.3 Proposed by Board of Directors.4 Prices translated at constant CHF exchange rates:USD=0.94;EUR=1.21;100

4、 JPY=1.17;GBP=1.49.5 With one of Roches top 25 selling products.6 Full-time equivalents.Making innovation accessibleRoche Annual Report 2013Roche delivered a strong performance in 2013,with a 22%increase in IFRS net income.At the 2014 AGM,the Board of Directors will propose a 6%increase in dividend

5、to CHF 7.80.This would be the 27 th such increase in as many years.Roche signed agreements with 160 partners,across a multi-tude of areas,including immunotherapy for cancer,antibiotics for multi-resistant bacteria and technologies for new diagnostic tests.John C.Reed became Head of Pharma Research a

6、nd Early Development.Prior to joining Roche he was CEO at Sanford-Burnham Medical Research Institute in California,United States.Roche announced plans to invest 800million Swiss francs in its global biologic medicine manufacturing network to meet increasing demand.Kadcyla became our first antibodydr